AEON Biopharma (NASDAQ:AEON – Get Free Report) had its price objective reduced by stock analysts at HC Wainwright from $6.00 to $5.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 405.00% from the stock’s previous close.
AEON Biopharma Price Performance
AEON Biopharma stock opened at $0.99 on Wednesday. AEON Biopharma has a fifty-two week low of $0.80 and a fifty-two week high of $17.17. The company’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $5.36.
AEON Biopharma (NASDAQ:AEON – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Equities research analysts predict that AEON Biopharma will post -0.91 EPS for the current fiscal year.
Institutional Inflows and Outflows
AEON Biopharma Company Profile
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Read More
- Five stocks we like better than AEON Biopharma
- How to Calculate Stock Profit
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Why Are Stock Sectors Important to Successful Investing?
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.